{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T14:34:12Z","timestamp":1793975652538,"version":"4.8.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Tuberculosis"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.tube.2020.101902","type":"journal-article","created":{"date-parts":[[2020,1,11]],"date-time":"2020-01-11T11:17:27Z","timestamp":1578741447000},"page":"101902","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Potential role of adjuvant drugs on efficacy of first line oral antitubercular therapy: Drug repurposing"],"prefix":"10.1016","volume":"120","author":[{"given":"Ritu","family":"Mishra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shri","family":"Krishan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Nasir","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prem","family":"Kapur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid Umer","family":"Khayyam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manju","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.tube.2020.101902_bib1","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3329\/jhpn.v28i2.4879","article-title":"Tuberculosis: a global health problem","volume":"28","author":"Zaman","year":"2010","journal-title":"J Health Popul Nutr"},{"key":"10.1016\/j.tube.2020.101902_bib2","series-title":"Global tuberculosis report 2018","author":"World Health Organization","year":"2018"},{"issue":"suppl_2","key":"10.1016\/j.tube.2020.101902_bib3","doi-asserted-by":"crossref","first-page":"S325","DOI":"10.1093\/infdis\/jis197","article-title":"Adjunct immunotherapies for tuberculosis","volume":"205","author":"Uhlin","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.tube.2020.101902_bib4","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/tmi.12018","article-title":"Costs of inpatient treatment for multi\u2010drug\u2010resistant tuberculosis in South Africa","volume":"1","author":"Schnippel","year":"2013","journal-title":"Trop Med Int Health"},{"key":"10.1016\/j.tube.2020.101902_bib5","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.ccm.2009.08.009","article-title":"Advances in immunotherapy for tuberculosis treatment","volume":"30","author":"Churchyard","year":"2009","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.tube.2020.101902_bib6","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1128\/MMBR.00032-13","article-title":"Host directed therapeutics for tuberculosis: can we harness the host?","volume":"77","author":"Hawn","year":"2013","journal-title":"Microbiol Mol Biol"},{"issue":"8","key":"10.1016\/j.tube.2020.101902_bib7","doi-asserted-by":"crossref","DOI":"10.1038\/nrd4696","article-title":"Towards host-directed therapies for tuberculosis","volume":"14","author":"Zumla","year":"2015","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"10.1016\/j.tube.2020.101902_bib8","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.4014\/jmb.1705.05032","article-title":"Host-directed therapeutics as a novel approach for tuberculosis treatment","volume":"27","author":"Kim","year":"2018","journal-title":"J Microb Biotechnol"},{"issue":"4","key":"10.1016\/j.tube.2020.101902_bib9","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1473-3099(13)70328-1","article-title":"New antituberculosis drugs regimens and adjunct therapies need advances and future prospects","volume":"14","author":"Zumla","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.tube.2020.101902_bib10","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.3389\/fmicb.2017.02452","article-title":"Repurposing and revival of the drugs: a new approach to combat the drug resistant tuberculosis","volume":"11","author":"Sharma","year":"2017","journal-title":"Front Microbiol"},{"issue":"4","key":"10.1016\/j.tube.2020.101902_bib11","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1582-4934.2001.tb00172.x","article-title":"Statins: mechanism of action and effects","volume":"5","author":"Stancu","year":"2001","journal-title":"J Cell Mol Med"},{"issue":"9","key":"10.1016\/j.tube.2020.101902_bib12","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/jac\/dku166","article-title":"Simvastatin increases the in vivo activity of the first-line tuberculosis regimen","volume":"69","author":"Skerry","year":"2014","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"10.1016\/j.tube.2020.101902_bib13","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/nrd1901","article-title":"Anti-inflammatory effects of statins: clinical evidence and basic mechanisms","volume":"4","author":"Jain","year":"2005","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.tube.2020.101902_bib14","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.mehy.2014.04.002","article-title":"Statin therapy may prevent the development of tuberculosis in the diabetics state","volume":"83","author":"Banerjee","year":"2014","journal-title":"Med Hypotheses"},{"issue":"5","key":"10.1016\/j.tube.2020.101902_bib15","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/infdis\/jit550","article-title":"Statin therapy reduces the Mycobacterium tuberculosis burden in human macrophages and in mice by enhancing autophagy and phagosome maturation","volume":"209","author":"Parihar","year":"2013","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.tube.2020.101902_bib16","first-page":"1570","article-title":"Statin adjunctive therapy enhances the activity of the first-line regimen against Tb in mice","volume":"71","author":"Karakousis","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"10.1016\/j.tube.2020.101902_bib17","first-page":"64651","article-title":"Statin treatment is associated with a decreased risk of active tuberculosis: an analysis of a nationally representative cohort","volume":"1","author":"Lai","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.tube.2020.101902_bib18","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01826-13","article-title":"Statins increase rifampin mycobactericidal effect","author":"Lobato","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.tube.2020.101902_bib19","doi-asserted-by":"crossref","first-page":"785","DOI":"10.4161\/auto.28072","article-title":"The AMPK-PPARGC1A pathway is required for antimicrobial host defense through activation of autophagy","volume":"20","author":"Yang","year":"2014","journal-title":"Autophagy"},{"issue":"6","key":"10.1016\/j.tube.2020.101902_bib20","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.pharep.2017.05.008","article-title":"Effect of antidiabetic drugs on bone metabolism: evidence from preclinical and clinical studies","volume":"69","author":"Adil","year":"2017","journal-title":"Pharmacol Rep"},{"issue":"263","key":"10.1016\/j.tube.2020.101902_bib21","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1126\/scitranslmed.3009885","article-title":"Metformin as adjunct antituberculosis therapy","volume":"6","author":"Singhal","year":"2014","journal-title":"Sci Transl Med"},{"issue":"6","key":"10.1016\/j.tube.2020.101902_bib22","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1073\/pnas.1417636112","article-title":"Immune-mediated antitumor effect by type 2 diabetes drug metformin","volume":"10","author":"Eikawa","year":"2015","journal-title":"Proc Natl Acad Sci"},{"issue":"6","key":"10.1016\/j.tube.2020.101902_bib23","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.dsx.2018.05.009","article-title":"Detrimental association between diabetes and tuberculosis: an unresolved double trouble","volume":"12","author":"Siddiqui","year":"2018","journal-title":"Diabetes Metab Syndrome"},{"issue":"3","key":"10.1016\/j.tube.2020.101902_bib24","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.bjid.2017.01.001","article-title":"Protective effect of metformin against tuberculosis infections in diabetic patients: an observational study of south Indian tertiary healthcare facility","volume":"21","author":"Marupuru","year":"2017","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.tube.2020.101902_bib25","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1046\/j.1365-2567.2002.01403.x","article-title":"The role of prostaglandin E2 in the immunopathogenesis of experimental pulmonary tuberculosis","volume":"106","author":"Rangel Moreno","year":"2002","journal-title":"Immunology"},{"issue":"2","key":"10.1016\/j.tube.2020.101902_bib26","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/infdis\/jit152","article-title":"Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis","volume":"15","author":"Vilaplana","year":"2013","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.tube.2020.101902_bib27","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cell.2013.03.022","article-title":"TNF dually mediates resistance and susceptibility to mycobacteria via mitochondrial reactive oxygen species","volume":"153","author":"Roca","year":"2013","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.tube.2020.101902_bib28","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/jac\/dkl486","article-title":"Aspirin and ibuprofen enhance pyrazinamide treatment of murine tuberculosis","volume":"21","author":"T Byrne","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.tube.2020.101902_bib29","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0065-230X(04)91004-4","article-title":"Histone deacetylase inhibitors","volume":"91","author":"Marks","year":"2004","journal-title":"Adv Cancer Res"},{"issue":"4","key":"10.1016\/j.tube.2020.101902_bib30","first-page":"328","article-title":"Autophagy induced by Valproic acid is associated with oxidative stress in glioma cell lines","volume":"12","author":"Fu J Shao","year":"2009","journal-title":"Neuro Oncol"},{"issue":"6","key":"10.1016\/j.tube.2020.101902_bib31","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1124\/mol.111.072314","article-title":"Valproic acid increases the formation of reactive oxygen species and induces apoptosis in postimplantation embryos: a role for oxidative stress in valproic acid-induced neural tube defects","volume":"80","author":"Tung","year":"2011","journal-title":"Mol Pharmacol"},{"issue":"1","key":"10.1016\/j.tube.2020.101902_bib32","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12916-016-0635-1","article-title":"Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis","volume":"14","author":"Zumla","year":"2016","journal-title":"BMC Med"},{"issue":"1","key":"10.1016\/j.tube.2020.101902_bib33","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1177\/0300891618784790","article-title":"IL-6\/IL-6R pathway is a therapeutic target in chemo resistant ovarian cancer","volume":"105","author":"Yousefi","year":"2019","journal-title":"Tumori J"},{"issue":"10","key":"10.1016\/j.tube.2020.101902_bib34","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1086\/598504","article-title":"Adalimumab treatment of life-threatening tuberculosis","volume":"48","author":"Wallis","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.tube.2020.101902_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004770","article-title":"Low doses of imatinib induce myelopoiesis and enhance host anti-microbial immunity","volume":"11","author":"Napier","year":"2015","journal-title":"PLoS Pathog"},{"issue":"5","key":"10.1016\/j.tube.2020.101902_bib37","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.chom.2011.09.010","article-title":"Imatinib-sensitive tyrosine kinases regulate mycobacterial pathogenesis and represent therapeutic targets against tuberculosis","volume":"10","author":"Napier","year":"2011","journal-title":"Cell Host Microbe"},{"issue":"40","key":"10.1016\/j.tube.2020.101902_bib38","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/j.1742-1241.2007.01320.x","article-title":"Zileuton: clinical implications of 5\u2010Lipoxygenase inhibition in severe airway disease","volume":"61","author":"Berger","year":"2007","journal-title":"Int J Clin Pract"},{"issue":"5","key":"10.1016\/j.tube.2020.101902_bib39","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S1473-3099(15)70053-8","article-title":"Adjunctive vitamin D for treatment of active tuberculosis in India: a randomized, double-blind, placebo-controlled trial","volume":"15","author":"Daley","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"13","key":"10.1016\/j.tube.2020.101902_bib40","doi-asserted-by":"crossref","first-page":"pp5201","DOI":"10.1073\/pnas.0801003105","article-title":"IL-15 as a mediator of CD4+ helps for CD8+ T cell longevity and avoidance of TRAIL-mediated apoptosis","volume":"105","author":"Perera","year":"2008","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.tube.2020.101902_bib41","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4103\/2277-9175.203162","article-title":"Levamisole as an adjuvant to short-course therapy in newly diagnosed pulmonary tuberculosis patients","volume":"6","author":"Shamkuwar","year":"2017","journal-title":"Adv Biomed Res"},{"issue":"3","key":"10.1016\/j.tube.2020.101902_bib42","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.ajpath.2014.11.003","article-title":"LAG3 expression in active Mycobacterium tuberculosis infections","volume":"185","author":"Phillips","year":"2015","journal-title":"Am J Pathol"},{"issue":"18","key":"10.1016\/j.tube.2020.101902_bib43","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1200\/JCO.2014.58.3708","article-title":"Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non\u2013small-cell lung cancer","volume":"33","author":"Gettinger","year":"2015","journal-title":"J Clin Oncol"}],"container-title":["Tuberculosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472979219301283?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472979219301283?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T08:42:45Z","timestamp":1761468165000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1472979219301283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":42,"alternative-id":["S1472979219301283"],"URL":"https:\/\/doi.org\/10.1016\/j.tube.2020.101902","relation":{},"ISSN":["1472-9792"],"issn-type":[{"value":"1472-9792","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential role of adjuvant drugs on efficacy of first line oral antitubercular therapy: Drug repurposing","name":"articletitle","label":"Article Title"},{"value":"Tuberculosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tube.2020.101902","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101902"}}